文献速递肺栓塞与肺血管病

Toll样受体3是肺动脉高压的治疗靶点

Toll-like Receptor 3 Is a Therapeutic Target for Pulmonary Hypertension.
PubMed 文献 · Am J Respir Crit Care Med · 2019-01-01

该研究探讨TLR3在肺动脉高压(PAH)中的表达与作用,并验证TLR3激动剂在临床前模型中的疗效。PAH患者肺组织和内皮细胞中TLR3表达降低,TLR3敲除小鼠在慢性缺氧/SU5416后肺动脉高压更严重;在大鼠模型中,高剂量Poly(I:C)通过上调TLR3减轻肺动脉高压和右心衰竭。

要点

  • PAH患者肺组织和内皮细胞中TLR3表达降低。
  • TLR3缺失加重慢性缺氧/SU5416诱导的小鼠肺动脉高压。
  • 高剂量Poly(I:C)在两种大鼠模型中减轻肺动脉高压和右心衰竭。

核心结论

  • TLR3表达降低促进内皮细胞凋亡和肺血管重塑,TLR3激动剂可减轻临床前肺动脉高压。

研究设计与样本

  • 研究检测PAH患者肺组织和内皮细胞中TLR3表达,并比较TLR3-/-与TLR3+/+小鼠在慢性缺氧和SU5416暴露后的肺动脉高压严重程度。
  • 在慢性缺氧或慢性缺氧/SU5416大鼠模型中,给予TLR3激动剂Poly(I:C)进行概念验证实验。

主要发现

  • PAH患者肺组织和内皮细胞中TLR3表达降低。
  • TLR3-/-小鼠在慢性缺氧/SU5416暴露后表现出更严重的肺动脉高压。
  • TLR3敲低促进内皮细胞通过其他胞内RNA受体进行双链RNA信号传导,并与更高的凋亡易感性相关。
  • Poly(I:C)通过IL-10增加大鼠内皮细胞中TLR3表达。
  • 高剂量Poly(I:C)在两种大鼠模型中减轻肺动脉高压,并减轻已建立肺动脉高压的右心衰竭。

临床怎么用

  • TLR3表达降低与PAH内皮细胞凋亡和肺血管重塑相关,提示TLR3通路是潜在治疗靶点。
  • TLR3激动剂Poly(I:C)在临床前模型中减轻肺动脉高压和右心衰竭,为后续转化研究提供依据。

局限性

  • 研究主要为临床前模型和体外实验,尚未在PAH患者中验证TLR3激动剂的疗效和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Pulmonary arterial hypertension (PAH) is characterized by vascular cell proliferation and endothelial cell apoptosis. TLR3 (Toll-like receptor 3) is a receptor for double-stranded RNA and has been recently implicated in vascular protection. OBJECTIVES: To study the expression and role of TLR3 in PAH and to determine whether a TLR3 agonist reduces pulmonary hypertension in preclinical models. METHODS: Lung tissue and endothelial cells from patients with PAH were investigated by polymerase chain reaction, immunofluorescence, and apoptosis assays. TLR3-/- and TLR3+/+ mice were exposed to chronic hypoxia and SU5416. Chronic hypoxia or chronic hypoxia/SU5416 rats were treated with the TLR3 agonist polyinosinic/polycytidylic acid (Poly[I:C]). MEASUREMENTS AND MAIN RESULTS: TLR3 expression was reduced in PAH patient lung tissue and endothelial cells, and TLR3-/- mice exhibited more severe pulmonary hypertension following exposure to chronic hypoxia/SU5416. TLR3 knockdown promoted double-stranded RNA signaling via other intracellular RNA receptors in endothelial cells. This was associated with greater susceptibility to apoptosis, a known driver of pulmonary vascular remodeling. Poly(I:C) increased TLR3 expression via IL-10 in rat endothelial cells. In vivo, high-dose Poly(I:C) reduced pulmonary hypertension in both rat models in proof-of-principle experiments. In addition, Poly(I:C) also reduced right ventricular failure in established pulmonary hypertension. CONCLUSIONS: Our work identifies a novel role for TLR3 in PAH based on the findings that reduced expression of TLR3 contributes to endothelial apoptosis and pulmonary vascular remodeling.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Farkas D, Thompson AAR, Bhagwani AR, et al. Toll-like Receptor 3 Is a Therapeutic Target for Pulmonary Hypertension. Am J Respir Crit Care Med. 2019. PMID: 30211629. doi:10.1164/rccm.201707-1370OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。